Product nameAnti-C7 antibody [EPR7036] (HRP)
See all C7 primary antibodies
DescriptionRabbit monoclonal [EPR7036] to C7 (HRP)
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human C7 aa 800 to the C-terminus. The exact sequence is proprietary.
Database link: P10643
- WB : HepG2, K562 and HUVEC whole cell lysates.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% Proclin
Constituents: 30% Glycerol, 1% BSA, PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab205857 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/5000. Detects a band of approximately 94 kDa (predicted molecular weight: 94 kDa).|
FunctionConstituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C7 serves as a membrane anchor.
Involvement in diseaseDefects in C7 are a cause of complement component 7 deficiency (C7D) [MIM:610102]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis.
Sequence similaritiesBelongs to the complement C6/C7/C8/C9 family.
Contains 1 EGF-like domain.
Contains 1 LDL-receptor class A domain.
Contains 1 MACPF domain.
Contains 2 Sushi (CCP/SCR) domains.
Contains 2 TSP type-1 domains.
modificationsC7 has 28 disulfide bridges.
- Information by UniProt
- C7 antibody
- CO7_HUMAN antibody
- complement component 7 antibody
- Complement component C7 antibody
All lanes : Anti-C7 antibody [EPR7036] (HRP) (ab205857) at 1/5000 dilution
Lane 1 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate
Lane 2 : K562 (Human erythromyeloblastoid leukemia cell line) Whole Cell Lysate
Lane 3 : HUVEC (Human Umbilical Vein Endothelial Cell) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 94 kDa
Observed band size: 94 kDa
Exposure time: 16 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab205857 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab205857 has not yet been referenced specifically in any publications.